

Medicines Management Committee Meeting BRIEF MINUTES: Wednesday 17th June 2020 9.00 am - 11.00 am via Zoom

Present:

(CHAIR) Dr Sophie Holden (SH), GP – Market Surgery

Dr Ravi Nalliagounder (RNa), GP - Greenside Surgery

Stuart Lakin (SL) - Head of Medicines Management - NHS Rotherham CCG

Govinder Bhogal - Deputy Head of Medicines Management - NHS Rotherham CCG

Raz Saleem (RS) - Prescribing Advisor - NHS Rotherham CCG

Gwen Yale (GY) - Senior Medicines Management Technician - NHS Rotherham CCG

Christelle Vanderbijl (CV) - PCN Pharmacist

In Attendance: Jessica France – Administration Officer, NHS Rotherham CCG

Item No.	Item Description	Discussion	Action By
103/20	Introductions	SH welcomed the group to the meeting.	
104/20	Apologies	Emma Batten (EB) – Lead Infection Prevention Nurse – NHS Rotherham CCG	
105/20	Quorum Check Minimum of 3 members to include: 1 x GP, 2 x Medicines Management Team Members, one of which should be the Head of Medicines Management or deputy and one prescribing support pharmacist from the Medicines Management Team.	The meeting was quorate in line with the Quoracy Guidance within the Terms of Reference.	
106/20	Declarations of Interest	RNa noted his standing declaration as he is an appointed member of the Local Medicines Committee (LMC) and is a Primary Care Network (PCN) Director. NH noted her deceleration of interest regarding the Incentive Scheme Payments item. SH / RNa noted their declaration regarding the FIS / QIS agenda item.	



107/20	Draft Minutes of the last meeting 3 June 2019 (for approval) and Matters Arising	SL provided an update on item 96/20 of the previous minutes. Avastin: ES has met with Osman Chohan and local opthalmologists. Locally there is no aseptic capacity to have this as current option (more staff and isolaters would be needed). Lucentis and Eyelea have 18 months before they come off patent and alternative biosimilars may then be available as an option. A local pathway is being developed using predicted patient numbers over the next few years. ACTION: ES to bring new pathway to MMC when available. JF to confirm that updated Emollient Guidance has been uploaded to the RCCG Website. ACTION: JF to action the above.	ES JF
108/20	Activity Log	There was no discussion regarding this item.	
109/20	FIS / QIS Performance 2019/20	RS provided an update to MMC and clarified information found in Enc 7 in relation to FIS/QIS. Similar figures were paid in comparison to last year. There were a total of 99 audits discussed for FIS/ QIS. 62 audits were approved No comments or major concerns were recorded for this item. ACTION: SL to take information to OE ACTION: RS to confirm exact audit total for SL to include in OE paper.	SL RS
110/20	Reporting Adverse Reactions via Yellow Card	This item is to be forwarded to the next MMC meeting. ACTION: JF to add item to appropriate meeting agenda.	JF

111/20	Telederm Advice to Prescribe	RS updated MMC on this item. Teledermatology are requesting GPs to initiate AMBER drugs to patients without being seen. Although some GPs may be able to counsel patients about the medication and possible side effects, it was agreed by RNa / SH that a patient is to be sent to dermatology when unsure of treatment. The hospital can then initiate and monitor the patient as per usual AMBER drug protocols. ACTION: SH / SL / RS to meet with Janet Sinclair-Pinder (JSP) to obtain advice on issue.	SH/SL/ RS
112/20	Hospital Drugs – recording onto GP Systems	RS plans to bring in a universal way of recording "hospital only "drugs in GP practice system. This is to aid safety e.g. for vaccines, drug interactions as well as consistency across the practices. This was felt to be helpful when the CCG were doing data trawling to look for patients who would need to shield during COVID. A robust system in place will help for future pandemics. **ACTION: JF to arrange separate meeting regarding this item with the names participants.** **ACTION: RS to bring guidance back to MMC when available.**	JF RS
113/20	Items for OE	CH Plan FIS / QIS Performance 2019/20	SL
114/20	Care Homes	We are currently working with Sheffield CCG to develop a database which will enable us to monitor work currently undertaken in care homes. It compromises of multiple modules using an external portal. We will initially be looking at recording activity in 3 areas: Interventions, Waste and Cost savings.	
115/20	Safety warnings from the MHRA, manufacturers and NHS Improvement	Yellow card reporting to be encouraged especially around COVID. She also informed MMC that for pregnancy prevention for Valproate, face-to-face meetings are not currently appropriate therefore a risk assessment must be carried out as an alternative.	

116/20	NICE	There was no discussion regarding this item.	
117/20	Traffic Light Update	There was no discussion regarding this item.	
118/20	Horizon Scanning	There was no discussion regarding this item.	
119/20	NHSE Accountable Care System (ICS) – Impact	SL noted that there are currently no formal updates from the ICS however there may be more information released to MMC in the coming weeks.	
120/20	 For Information: Barnsley APC Minutes Barnsley APC Memo – Memo & Enclosure Doncaster & Bassetlaw APC RDASH Draft MMC Minutes Sheffield Area Prescribing Group 	There was no discussion regarding this item.	
121/20	Feedback from RMOG	Biological pathway for psoriasis was discussed. It was agreed that a document supporting the guideline would be developed.	
122/20	Items for RMOG, Items for Escalation or Additions to the Risk Register	Dapsone (Amber)	

123/20	Urgent Issues & Appropriate Escalation	None identified	
124/20	Risks Raised	There was no discussion regarding this item.	
125/20	Any Other Business	SL discussed that unidentified prescribers at practices who work across PCNs may cause issues as the main practice risks being charged inappropriately. The prescriber will have to be registered at ALL sites as a locum	
126/20	Date of next meeting	Date and time of next meeting: Wednesday 1 st July from 9.00am – 11.00am via Zoom.	